autologous anti-cd19 car-t cells caba-201
autologous anti-cd19 car-t cells caba-201: 5 clinical trials tracked.
autologous anti-cd19 car-t cells caba-201 evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about autologous anti-cd19 car-t cells caba-201, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 1 study sponsors
Clinical Trial Registry Records (5)
RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis
Primary endpoint: Primary (Part A: Dose Escalation) incidence and severity of adverse events
RESET-MG: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravis
Primary endpoint: To evaluate incidence and severity of adverse events (AEs)
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis
Primary endpoint: Phase 1/2: To evaluate incidence of adverse events
A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus Erythematosus
Primary endpoint: To evaluate incidence of adverse events
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris
Primary endpoint: Adverse events, including Dose Limit Toxicity